We are committed to supporting clinicians during these immensely difficult and challenging times and to ensuring that our patients continue to receive the best possible care without delay. This page has the latest information on how we continue to treat patients, clinical protocols, how you can work with us, frequently asked questions and the latest clinician updates.
Our specialist cancer centres are open and we are undertaking robust screening and infection control procedures as well as secure video consultations to ensure we are able to maintain the safest possible environment for patients and the staff who care for them. We have also increased our capacity to support access to diagnostics and some of our advanced technologies such as hypofractionated radiotherapy to minimise treatment times.
We are accepting referrals for chemotherapy and radiotherapy. For patients starting or continuing cancer treatment, each case will be reviewed individually by an eMDT which can also involve the referring clinician.
For more information on how to refer a patient, please contact one of our referrer engagement managers REM@genesiscare.co.uk
Our clinical reference groups continue to review treatment protocols and techniques against current evidence and the guidelines from the Royal College of Radiologists, ESTRO and other clinical authorities. These have been revised and published for the main tumour types and accessible below.
You can also access the adapted treatment protocols from the Royal College of Radiologists.
We appreciate that our surgical and oncology teams will face difficult decisions throughout the pandemic. We have accelerated the roll-out of our eMDT platform to ensure all best practice protocols are maintained. This system facilitates clinician peer review and combines videoconferencing and data technology to enable remote collaboration in a secure environment that tracks the patient journey.
We are increasing access to our diagnostic services, in particular One Stop Breast Clinics, UrologyHubs and Rapid Access Haematology and Head and Neck Services. We know these services are critical, not only to take pressure off NHS services but also to ensure that patients continue to receive a timely diagnosis. Find out more about our diagnostic clinics and make a referral
As the COVID-19 situation continues to change, we continually review and adjust our processes and policies to ensure our staff and patients remain safe and that we are able to treat patients without delay. We have capacity in various parts of the pathway and we’re working incredibly hard to ensure that we expand and fast track services at this critical time.
We are always looking to collaborate with talented consultants. We can help you build your private practice with practice management systems, website and marketing support and free consultation rooms.
We welcome requests from individuals and academic institutions to access our state-of-the-art equipment and clinical support for treatment and research. To find out more about practising privileges or research opportunities, please contact us here REM@genesiscare.co.uk.
GenesisCare use Zoom in Telehealth consultations to provide an ongoing service and consultations in a safe environment for all patients and referrers. We have a Zoom custom configuration to assist in managing your patient consultations by providing a virtual waiting room for patients. Zoom is the same application used for virtual meetings across the business, with a custom configuration applied to your account to assist in managing your patient consultations by providing a virtual waiting room for patients.
Along with recent COVID-19 challenges, the benefits of Telehealth include:
Find out more about using zoom for telehealth here.
Can my patient transfer to GenesisCare for their treatment?
We often receive enquiries from clinicians and patients directly who are anxious to continue cancer treatment without delay. Typically, our patients are funded through private medical insurance but during this time we have reduced our prices to make it more accessible to those who want to fund the cost of their own treatment.
What is an example of an advanced technology that could benefit patients now?
Stereotactic ablative radiotherapy (SABR) enables treatment of a number of tumour types using a small number of fractions – five or less. This hypofractionated approach is non-invasive and has obvious benefits in limiting treatment episodes or avoiding surgery. We have significant expertise and capacity across our network to treat lung, pancreas and liver, brain, prostate and oligometastatic disease (all cancers) with SABR. We offer these hypofractionated radiotherapy treatments where possible and may delay any chemotherapy that will compromise the patient’s immune system, putting them at higher risk of becoming unwell from respiratory illness. We’re working with some of the country’s leading SABR specialists and we are ready to treat patients alongside our existing cases. We are also treating patients for pancreas and lung using the UK’s first MRIdian MR linacs at our centres in Oxford and Cromwell Hospital in London.
Who decides your treatment protocols and how do you ensure treatment protocols are safe?
Our clinical reference groups and UK Leadership Team work closely with the NHS, RCR, ESTRO and other surgical and oncology associations to ensure that our revised clinical protocols are aligned with national clinical guidelines.
All patient referrals for new protocols are reviewed by our clinical reference groups and clinical advisory team to ensure compliance with eligibility criteria.
Will you be advising patients to continue with treatment?
Clinicians should continue to discuss the risk and benefits of having treatment at this time with patients. Informed consent is required and should be clearly noted.
We have prepared a summary of scenarios exploring absolute survival benefit and potential risks in a variety of common chemotherapy. This is available here.
Will you continue chemotherapy treatment (solid and haem cancers) for all patients in vulnerable groups (as defined by NICE guidelines)?
Our clinical reference groups and UK Leadership Team work closely with the NHS, NICE, ESMO and other oncology and haematology associations to ensure that our revised chemotherapy protocols are aligned with national clinical guidelines for solid and haematological malignancies.
We have therefore revised our protocols to include:
Typically, how long does it take to start a course of treatment from referral?
At GenesisCare we receive referrals from two main pathways:
We endeavour to treat patients within five to seven days from referral. These timings depend on whether we have all the histology results and relevant clinical dataset available for the cancer MDTs to make treatment decisions and to comply with regulatory requirements such as IR(ME)R 2017, otherwise we operate on full workforce capacity in terms of radiotherapy planners, physicists, therapy radiographers and chemotherapy nurses.
Will you be treating COVID-19 patients?
Wherever safe to do so, patients will have their treatment delayed until after their symptoms have resolved and isolation period is over. However, there will be occasions where it is clinically necessary for treatment to continue.
Will you still be providing spacer insertions under general anaesthetic for prostate radiotherapy treatment?
Your patients can access spacer insertions under local anaesthetic at:
Keep up to date with our latest updates for clinicians. As the COVID-19 pandemic continues, we aim to keep clinicians up to date on our treatment status, centre preparedness and business continuity plans. Treatment continues as usual and we are prepared to treat all patients without delay. Ensure you filter by clinician news on our news page, providing you with our latest updates: